Date of Document: March 29, 2024
CURRICULUM VITAE

Lubna N. Chaudhary MD
Associate Professor
Department of Medicine
Division of Hematology and Oncology - Medicine

OFFICE ADDRESS:
Froedtert Hospital
9200 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:
1997 - 1998 Higher Secondary School Certificate (Pre-Medical), Saudi Arabian International School, Al-Khobar. KSA
1999 - 2005 M.B.,B.S. Honors (Punjab University), King Edward Medical College, Lahore, Pakistan
2014 - 2016 Masters in Clinical and Translational Science, Medical College of Wisconsin, Milwaukee, WI

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
07/01/2009 - 06/30/2010 Internship in Internal Medicine, West Virginia University, Morgantown, WV
07/01/2010 - 06/30/2012 Residency in Internal Medicine, West Virginia University, Morgantown, WV
07/01/2012 - 07/31/2013 Fellowship in Hematology and Oncology, West Virginia University, Morgantown, WV
10/01/2013 - 08/31/2015 Fellowship in Hematology and Oncology, Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI

FACULTY APPOINTMENTS:
11/2015 - 06/2021 Assistant Professor of Medicine, Medicine, Hematology and Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Ave., Milwaukee, WI 53226
07/2021 - Present Associate Professor of Medicine, Medicine, Hematology and Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Ave., Milwaukee, WI 53226

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
07/01/2017 - Present Associate Program Director, Solid Tumor, Hematology Oncology Fellowship Program, Medicine, Hematology and Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Ave., Milwaukee, WI 53226
01/01/2020 - Present Liaison for National Clinical Trials, Lead Academic Participating Sites (NCTN LAPS) Network, Breast Disease Oriented Team (DOT), Medicine, Hematology and Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226
02/01/2021 - Present Co-Leader, Breast Multidisciplinary Science Disease Oriented Team, Medicine, Hematology and Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226
11/01/2021 - Present Vice Chair, Breast Disease Oriented Team (DOT), Medicine, Hematology and Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226

HOSPITAL STAFF PRIVILEGES:
2015 - Present Attending Physician, Breast Cancer Care Clinic, Froedtert Clinical Cancer Center, 9200 W. Wisconsin Ave., Milwaukee, WI 53226
2015 - Present Attending Physician, Medicine, Hematology Oncology Service, Froedtert St. Joseph's Hospital, 3200 Pleasant Valley Road, West Bend, WI 53095
2015 - Present Attending Physician, Medicine, Hematology Oncology Service, Froedtert Hospital, 9200 W. Wisconsin Ave., Milwaukee, WI 53226
2015 - Present Attending Physician, Hereditary Cancer Management Clinic, Froedtert Cancer Center, 9200 W. Wisconsin Ave., Milwaukee, WI 53226

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
Internal Medicine
08/22/2012
08/22/2032
Medical Oncology
08/27/2015
08/27/2025
   
Certificates
Issued By Issue DateExpiration
USMLE Step 1: 80/197 Step 2 CK: 94/233 Step 2 CS: Passed Step 3: 86/207
ECFMG
2006
None
    

Licensure
Number Issue DateExpiration
Wisconsin License
61276-20
2013
2025
    

AWARDS AND HONORS:
1998 Board of Intermediate and Secondary Education, merit Scholarship
2005 Lt. General Burki's Gold Medal in Clinical Ophthalmology, King Edward Medical College, Lahore
2005 First Division in Second and Final Professional examinations, King Edward Medical College, Lahore
2013 Oncology Trainees Travel Award, Conquer Cancer Foundation of ASCO
2016 Faculty Development Award, Medical College of Wisconsin
2020 Top Doctors- Medical Oncology, Castle Connolly
2020 Top Oncologist, Wisconsin Magazine Top Doctors
2021 America's Most Honored Doctors , The American Registry
2021 Top Oncologist, Wisconsin Magazine Top Doctors
2021 Top Doctors- Medical Oncology, Castle Connolly
2022 Exceptional Women in Medicine, Castel Connolly
2022 Top Doctors- Medical Oncology, Castle Connolly
2023 Top Doctors- Medical Oncology, Castle Connolly
2023 Exceptional Women in Medicine, Castel Connolly

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
2005 - Present Member of the Pakistan Medical and Dental Council
2009 - Present Associate Member of the American College of Physicians
2012 - Present American Society of Clinical Oncology
2018 - Present NSABP Foundation Early Phase Trials Group
2018 - Present NRG Oncology Breast Committee
2018 - Present NRG Oncology Translational Research Sub Committee

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Editorial Board
2016 - Present Clinics in Oncology-Breast Cancer
2021 - Present Associate Editor-Hematology/Oncology and Stem Cell Therapy
Ad-Hoc Reviewer
Clinical Breast Cancer, American Journal Of Clinical Oncology, Translational Oncogenomics, International Journal of cancer Research and molecular mechanisms

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
‘Student-Centered Pipeline to Advance Research in Cancer Careers (SPARCC) for Underrepresented Minority Students’
Source:
NIH R25 education grant
Role:
Co-Investigator (1% effort)
PI:
Rader, Janet MD
Dates:
09/28/2018 - 08/31/2023
Direct Funds:
$1,048,219 (The purpose of the grant is to improve the recruitment and retention of underrepresented minority students in biomedical research. Our overarching goals are to (a) actively identify and educate a diverse group of students who will subsequently pursue careers as clinical research professionals or obtain advanced degrees in cancer research, and (b) improve diversity and culturally responsive care in the field of clinical cancer research. My role is to mentor and educate our underrepresented minority undergraduate students enrolled to this summer research program by providing lectures and one-one clinic sessions to help build a career in clinical cancer prevention, treatment and care.)
  
Title:
“WNT pathway-driven anti-estrogen therapy resistance in breast cancer.”
Source:
NIH R01
Role:
Co-Investigator (5% effort)
PI:
Rui, Hallgeir MD
Dates:
12/01/2022 - 11/30/2027
Direct Funds:
$3,279,697 (This transdisciplinary research project is expected to provide 1) new mechanistic and targetable pathway insights relevant for therapy-resistance in aggressive estrogen receptor-positive breast cancers with a mixed luminobasal phenotype, 2) improved diagnostic tools to identify breast cancers with these features, and 3) preclinical support for new therapeutic strategies for patients diagnosed with these aggressive tumors.)
  
Title:
“Phase II Study of PD-1 Inhibition with Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients undergoing Standard Neoadjuvant Chemotherapy.”
Source:
Regeneron Pharmaceuticals
Role:
Principal Investigator
PI:
Chaudhary, Lubna MD
  
Pending
Peer Review
Title:
‘Overcoming Endocrine Resistance by Targeting Genomic Instability in Metastatic Luminal B Breast Cancers’
Source:
NIH R01
Role:
Co-Investigator (2% effort)
PI:
Sun, Yunguang
Direct Funds:
$427,354 (The objective of this R01 is to assess role of DNA repair inhibitors in ER+ endocrine responsive and endocrine resistant breast cancer tumors to assess BRCA 1 and 2 pathway and genomic instability. My role in this project is to provide medical oncology expertise as well as provide specimens from my neoadjuvant endocrine therapy clinical trial funded independent of this R01 grant. )
  
Title:
‘Advanced Omic Molecular Analyses to Assess Mechanisms of Endocrine Resistance After Short Term Neoadjuvant Endocrine Therapy in Patients with Hormone Receptor-Positive HER2-negative Breast Cancer’
Source:
Our Patient Project Program- MCW Cancer Center
Role:
Principal Investigator (5% effort)
PI:
Chaudhary, Lubna MD
Direct Funds:
$65,000 (This project aims to assess endocrine resistance mechanisms in response to neoadjuvant endocrine therapy in early stage ER+ breast cancer. HER2 RTK pathway and other resistance mechanisms will be assessed by advanced omic level analyses to study changes in tumor microenvironment. )
  
Title:
‘Surrogate Blood Biomarkers for Risk Prediction of Breast Cancer Treatment-Related Cardiotoxicity’
Source:
NIH R01
Role:
Co-investigator (5% effort)
PI:
Bosnjak, Zeljko MD
Direct Funds:
$3,202,705 (The goal of this study is to establish blood biomarkers for risk prediction of anthracycline particularly doxorubicin induced cardiotoxicity in breast cancer patients. Patient neutrophils and peripheral blood mononuclear cells will be assessed prior to chemotherapy to identify predictive changes. We will also assess pluripotent stem cell-derived cardiomyocytes to determine doxorubicin effects. My role in this project is to identify eligible patients and assist in patient accrual to the study, analysis of results and manuscript writing. )
  
Title:
‘Quantification of Treatment Related Changes in Breast Cancer Cells and Tumor Microenvironment’
Source:
NIH R01
Role:
Co-Investigator (5% effort)
PI:
Rui, Hallgeir MD
Direct Funds:
$1,964,000 (This R01 project will support radically new methodological approaches to standardized and quantitative IHC analyses of tumor markers and lead to novel predictive and prognostic markers. The specimens from my neoadjuvant endocrine therapy IIT will be used for one of its aims. The project is centered on breast cancer and will assess novel methodologies, immune markers and RTK pathway changes. )
  
Prior
Peer Review
Title:
“An Exploratory Study of Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive HER2-Negative Node-Negative Breast Cancer Patients to Assess Responses and Mechanisms of Endocrine Resistance.”
Source:
Rock River Foundation and the MCW Cancer Center
Role:
Principal Investigator (3% effort)
PI:
Chaudhary, Lubna MD
Dates:
03/01/2018 - 02/28/2020
Direct Funds:
$87,500 (The goal of this exploratory study is to investigate molecular and gene expression changes in patients with HR+ HER2 negative early stage breast cancer treated with neoadjuvant endocrine therapy for 4 weeks. By comparing pre- and post-treatment changes in the same patient, this valuable approach will allow for identification of key predictive and prognostic markers. Annual patient followup is ongoing. )
  
Title:
“Phase II Study of PD-1 Inhibition with Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients undergoing Standard Neoadjuvant Chemotherapy.”
Source:
Advancing a Healthier Wisconsin Research and Education Program (AHW REP). MCW CTSI Mentored Career Development Award KL2 grant
Role:
Principal Investigator (75% effort)
PI:
Chaudhary, Lubna MD
Dates:
03/15/2020 - 08/31/2021
Direct Funds:
$206,250 (The objective of this career development project is to determine the benefit of neoadjuvant PD-1 axis blockade plus standard chemotherapy in patients with high risk breast cancers by assessing tumor responsiveness. This study will offer the unique opportunity to assess the responsiveness of breast tumors positive for PD-L1 or PD-L2 to neoadjuvant PD-1 inhibition plus standard neoadjuvant chemotherapy. Patient accrual is ongoing)
  
Title:
‘Quantitiative Analysis of HER2 Up-regulation in Luminal Breast Cancer in Response to Neoadjuvant Endocrine Therapy’
Source:
R03 NIH/NCI grant
Role:
Principal Investigator (5% effort)
PI:
Chaudhary, Lubna MD
Dates:
04/01/2021 - 03/31/2023
Direct Funds:
$113,824 (This project will assess advanced immunohistochemistry and quantile protein analyses to assess changes in HER2 status using pre-and post-neoadjuvant endocrine therapy specimens from the recently completed IIT neoadjuvant clinical trial. Advanced metrics will be used to assess HER2 in biopsy specimens and develop statistical models to predict HER2 upregulation in post-treatment. )
  
Title:
AZ-D2270C00020-BRE253
Source:
AstraZeneca
Role:
Institutional PI
  
Title:
SCRI- GO29831-BRE261
Source:
F. Hoffmann-La Roche Ltd
Role:
Institutional PI
  

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Local
“The Next era of ER-Positive Breast Cancer Treatment”, Fourth Annual Wisconsin Review of San Antonio Breast Cancer Symposium, Milwaukee WI, 01/26/2019
“Genetic Testing for ALL Breast Cancers: The Why”, Milwaukee, WI, 05/29/2019
“Genomic Testing and Personalized Treatments for Breast Cancer”, MCW Dept of Surgery 2020 Surgical Oncology Symposium, Medical College of Wisconsin, Milwaukee, WI, 10/28/2020
“Metastatic Breast cancer- Equity, Treatments and Clinical Trials”, WI Breast Cancer Coalition- Knowledge is Power Symposium, MD Panel Discussion, 02/18/2021
“Endocrine Resistance in Luminal Breast Cancer”, MCW Cancer Center Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 05/20/2021
“Breast Cancer- Screenings, Types and Management”, Breast Cancer Awareness and Prevention Event, Nigerian Community in Milwaukee, 10/02/2021
“Endocrine Resistance in Luminal Breast cancer”, MCW Department of Medicine Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 01/14/2022
 
Regional
“Endocrine Resistance in Hormone Positive Breast Cancer”, 7th Annual Hematology Oncology Symposium, Green Bay, WI, 11/10/2018
“ER+ Breast Cancer- SABCS 2020 Highlights”, NSABP Foundation- Preclinical and Early Phase Meeting, 02/16/2021
“Updates in Triple Negative Breast Cancer- SABCS 2021 Highlights”, WI Review of SABCS 2021, Wisconsin Association of Hematology and Oncology (WAHO), 01/29/2022
“Treatment Management Updates in HER2-Positive and HER2-Low Breast Cancer”, OncLive State of the Science Summit- Breast Cancer, Madison, WI, 09/06/2023
“Management Updates in ER+ Breast Cancer”, WI Review of SABCS 2023, Wisconsin Association of Hematology and Oncology (WAHO), 02/03/2024
 
National
“Endocrine Resistance in Luminal Breast Cancer”, Dept of Medicine Grand Rounds, Roswell Park Comprehensive Cancer Center, 10/13/2023
 
International
“Navigating Fellowship Match: Journey Beyond Residency”, Association of Physicians of Pakistani Descent of North America (APPNA), Young Physicians Committee Panelist, Virtual event, 05/14/2022
“Successful Fellowship Match Discussion”, Association of Physicians of Pakistani Descent of North America (APPNA)- Physicians Committee Panelist, Virtual event, 05/28/2023
 

COMMITTEE SERVICE:
Medical College of Wisconsin
2016 - Present MCW Recognition Task Force Committee, Hematology and Oncology, Medicine, Medical College of Wisconsin
2017 - Present Fellowship Recruitment Committee, MCW Hem/Onc Fellowship Program, Hematology and Oncology, Medicine, Medical College of Wisconsin
2017 - Present Clinical Competency Committee (CCC), MCW Hem/Onc Fellowship Program, Hematology and Oncology, Medicine, Medical College of Wisconsin
2017 - Present Program Evaluation Committee (PEC), MCW Hem/Onc Fellowship Program, Hematology and Oncology, Medicine, Medical College of Wisconsin
2021 - Present Faculty Recruitment Committee, Surgical Oncology, Medicine, Medical College of Wisconsin
2022 - Present Grant Reviewer and Study Section Member, MCW CC Pilot, Hematology and Oncology, Medicine, Medical College of Wisconsin
 
Hospital
2021 - Present Breast Care Clinic Operational Committee, Froedtert Cancer Center
2021 - Present Breast Steering Committee FMF, Froedtert Menomonee Falls Cancer Center
2021 - Present Breast Steering Committee FMLH, Froedtert Cancer Center
2021 - Present Breast Cancer Clinical Leader, Faculty Recruitment Committee, Froedtert Cancer Center
2023 - Present Breast Program Leadership Committee, Froedtert Cancer Center
 

MEDICAL COLLEGE TEACHING ACTIVITIES:
Community/Lay Public
09/14/2016 " Triple Negative Breast Cancer: Clinical Overview", Cancer Center Board Meeting
09/27/2016 "Clinical Trials for Metastatic Breast Cancers at MCW", Metastatic Breast Cancer Support group Meeting
11/30/2016 “Types of Breast Cancer, Treatment and Future Directions”, Fall Community Education, Community Memorial Hospital
05/01/2018 “Latest Treatment Options by Subtype – Estrogen Positive”, Wisconsin Metastatic Breast Cancer Symposium- Susan Komen
11/09/2018 “Clinical Trials and a New Paradigm Shift”, Breast Cancer 101: What you need to know. A community CME event.
05/20/2021 “Endocrine Resistance in Luminal Breast Cancer”, MCW Cancer Center Grand Rounds
10/02/2021 “Breast Cancer- Screenings, Types and Management”, Nigerian Community in Milwaukee, Breast Cancer Awareness and Prevention Event
 
Medical Student Education
01/14/2018 - Present Clinical Apprenticeship Preceptor, Teaching clinical skills to MS1
 
Resident and Fellow Education
03/25/2016 "Treatment of HER2 positive breast cancer", Hematology/Oncology Fellows core lecture series
08/23/2016 "Treatment of Breast cancer: Medical and Surgical aspects", Surgery residents core lecture series
03/31/2017 “Management of breast cancer patients”, Hematology/Oncology Fellows core lecture series
03/12/2018 Neoadjuvant treatment in HER2 positive breast cancer patients”, Hematology/Oncology Fellows core lecture series
03/15/2019 “Updates in treatment for HER2 positive breast cancer patients”, Hematology/Oncology Fellows core lecture series
02/28/2020 “Recent approvals in treatment of breast cancer”, Hematology/Oncology Fellows core lecture series
05/25/2021 “Treatment of HER2 positive breast cancer”, Hematology/Oncology Fellows core lecture series
05/11/2022 “Breast Cancer Screenings, Types and Management”, IM Resident and intern lecture series
10/22/2022 “Treatment of HER2 positive breast cancer”, Hematology/Oncology Fellows core lecture series
10/02/2023 “Treatment of HER2 positive breast cancer”, Hematology/Oncology Fellows core lecture series
 

MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:
Medical Students
Ismail Abdalah, MCW, 1/2018-1/2019, Amanda Walsh, MCW, 1/2019- 1/2020, Kelly Renne Cotchett, 1/2020- present, Thomas Luo, 1/2020- 1/2021, Ashley Stahnke. 1/2021- 1/2022, Ashanti Johnson 1/2022-12/2022, Medical College of Wisconsin, 01/2018 - 12/2023 Clinical Apprenticeship Preceptor for MS1, Teach patient care skills, practice and system based learning. Student rotated with me on a weekly basis in outpatient breast clinic.
Alexandra Harris, Medical College of Wisconsin, 2021 - Present Quality Improvement and Patient Safety Pathways (QUIPS) Advisor, Correlation of neighborhood disadvantage and socioeconomic status with stage at diagnosis of breast cancer- Retrospective chart review: ASCO 2023 Publication abstract.
Kelly Cotchet, Medical College of Wisconsin, 2021 - Present Quality Improvement and Patient Safety Pathways (QUIPS) Advisor, Assessment of depression screening tools in breast cancer to identify high risk patient population. Retrospective chart review study: SABCS 2022 Poster Presentation
 
Residents
Ahmad Hanif, MCW, Hospitalist, Medical College of Wisconsin, 2015 - 2016 research mentor, data collection and manuscript writing, Published. WMJ. 2018 Jun;117(2):62-67
Zeeshan Jawa, MCW, Hem/Onc fellow, Medical College of Wisconsin, 2015 - 2018 research mentor, data collection, manuscript writings, publications, and presentations, Published. WMJ. 2018 Jun;117(2):62-67, Journal of Cancer 2022; 13(8): 2472-2476.
Hope Wilkinson, MCW Surgery resident, Medical College of Wisconsin, 2018 research mentor, review article, Published. Surg Oncol Clin N Am. 2018 Jan;27(1):141-153
Joanna Zurko, MCW, Hem/Onc fellow, Medical College of Wisconsin, 2019 research mentor, data collection, manuscript writing, ASCO 2021 publication abstract.
Claire Griffiths, MCW, Hem/Onc fellow, Medical College of Wisconsin, 2020 research mentor, manuscript writing, Published. JAMA Oncol. 2021 Aug 1;7(8):1239-1240
Michael Pierro, MCW, Hem/Onc fellow, Medical College of Wisconsin, 2022 research mentor, data collection, manuscript writing, Published. JAMA Oncol. 2023 Feb 16. doi: 10.1001. Another manuscript accepted to WMJ.
Kathleen Monahan, MCW, Hem/Onc fellow, Medical College of Wisconsin, 2022 research mentor, data analysis, abstract writing, SABCS 2022 Poster presentation.
Nicole Held, MCW, Hem/Onc fellow, Medical College of Wisconsin, 2023 - Present research mentor, data collection, analysis, writeup, Multi-institutional retrospective chart review on real world outcomes of Sacituzumab in TNBC.
 


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Hamadani M., Awab A., Chaudhary L., Tfayli A.: "Relative Efficacy of Ondansetron, Granisetron, Dolasetron and Palonosetron in controlling Acute Nausea and Vomiting associated with Platinum-based chemotherapy." J Oncol Pharm Pract. 2006 June;12(2):67-68.
2. Hamadani M., Chaudhary L.: "McCune-Albright Syndrome." Medical Journal of Australia. 2006 December;185(11/12):597.
3. Hamadani SM, Chaudhary L.: "Limitations of Sokal score in patients with chronic myeloid leukemia." J Coll Physicians Surg Pak. 2007 Mar;17(3):182-3.
4. Hamadani M., Chaudhary L., Awan FT., Khan JK., Kojouri K., Ozer H., Tfayli A.: "Management of platinum-based chemotherapy-induced acute nausea and vomiting. Is there a superior serotonin receptor antagonist?" J Oncol Pharm Pract. 2007 June;13(2):69-75.
5. Chaudhary L., Wilkinson R., Jordan C., Price A., Filburn S., Abraham J.: "Nasal Septum Perforation induced by Bevacizumab Therapy in Patients with Breast Cancer: Case Report and Literature Review." Community Oncology. 2012 Aug;9(8):259-262.
6. Chaudhary LN., Bailey NG., Vos JA., Stotler CJ.: "Unique association of myeloid neoplasm with eosinophilia and abnormalities of PDGFRA with TTP." WV Med J. 2013 Mar/Apr;109(2):6-9.
7. Kelly KM., Ajmera M., Bhattacharjee S., Vohra R., Hobbs G., Chaudhary L., Abraham J., Agnese D.: "Perception of cancer recurrence risk: More information is better." Patient Educ Couns. 2013 Mar;90(3):361-6.
8. Chaudhary L., Hamadani M.: "Management strategies for follicular lymphoma patients in remission after modern frontline chemoimmunotherapies." J Blood Disorders Transf. 2013 January;4(1):1000e105
9. Chaudhary L., Awan F., Cumpston C., Leadmon S., Watkins K., Tse W., Craig M., Hamadani M.: "Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF." J Clin Apharesis. 2013 Oct;28(5):359-367.
10. Chaudhary L., Kharfan-Dabaja MA., Hari P., Hamadani M.: "Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?" Bone Marrow Transplant. 2013 Nov;48(12):1489-96.
11. Chaudhary LN., Wen S., Xiao J., Swisher AK., Kurian S., Abraham J.: "Third generation adjuvant chemotherapy associated weight change in breast cancer patients." J Community Support Oncol, 2014 Oct;12(10):355-360.
12. Chaudhary LN., Knapp S., Wen S., Xiao J., Marano G., Kurian S., Layne G., Jacobson G., Abraham J. "Radiation exposure from diagnostic procedure in patients with newly diagnosed breast cancer." J Community Support Oncol , 2015 Jan; 13(1):27-29.
13. Chaudhary LN., Jawa Z., Szabo A., Visotcky A., Chitambar CR. "Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score." Hematol Oncol Stem Cell Ther. 2016 Jan 18.
14. Chaudhary LN, Wilkinson KH, Kong A. Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy? Surg Oncol Clin N Am. 2018 Jan;27(1):141-153.
15. Chaudhary LN, Jawa Z, Hanif A, Szabo A, Kamaraju S, Cheng YC, Chitambar CR. Does Progesterone Receptor Matter in the Risk of Recurrence for Patients With Ductal Carcinoma in Situ? WMJ. 2018 Jun;117(2):62-67.
16. Chaudhary LN. Early stage triple negative breast cancer: Management and future directions. Semin Oncol. 2020 Aug;47(4):201-208. PMCID: PMC7446736
17. Kamaraju S, Fowler AM, Weil E, Wisinski KB, Truong TH, Lehr M, Chaudhary LN, Cheng YC, Chitambar CR, Rui H, Yee D, Lange C. Leveraging Antiprogestins in the Treatment of Metastatic Breast Cancer. Endocrinology. 2021 Aug 01;162(8).
18. Chaudhary LN. Clinical and Psychosocial Challenges of Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years. JCO Oncol Pract. 2021 Jun;17(6):317-319. PMCID: PMC8258001
19. Griffiths C, Connelly J, Chaudhary LN. Sudden Paralysis in a 39-Year-Old Woman With Metastatic Breast Cancer. JAMA Oncol. 2021 Aug 01;7(8):1239-1240.
20. Sridhar N, Glisch C, Jawa Z, Chaudhary LN, Kamaraju S, Burfeind J, Charlson J, Chitambar CR, Jorns JM, Cheng YC. Androgen receptor expression in patients with triple negative breast cancer treated with neoadjuvant chemotherapy: a single institution study. J Cancer. 2022;13(8):2472-2476. PMCID: PMC9174868
21. Chervoneva I, Peck AR, Sun Y, Yi M, Udhane SS, Langenheim JF, Girondo MA, Jorns JM, Chaudhary LN, Kamaraju S, Bergom C, Flister MJ, Hooke JA, Kovatich AJ, Shriver CD, Hu H, Palazzo JP, Bibbo M, Hyslop T, Nevalainen MT, Pestell RG, Fuchs SY, Mitchell EP, Rui H. High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer. JCO Precis Oncol. 2023 Jan;7:e2100498. PMCID: PMC9928763
22. Pierro MJ, Zhang AJ, Chaudhary LN. Worsening Rash in a Patient With Metastatic Breast Cancer. JAMA Oncol. 2023 Apr 01;9(4):564-565.
23. Chaudhary LN, Jorns J, Sun Y, Cheng YC, Kamaraju S, Burfeind J, Gonyo M, Kong A, Patten C, Yen T, Cortina C, Carson E, Johnson N, Bergom C, Tsaih SW, Banerjee A, Wang Y, Chervoneva I, Weil E, Chitambar CR, Rui H. Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy. Res Sq. 2023 Apr 07. PMCID: PMC10104267
24. Rogers C, Cobb AN, Lloren JIC, Chaudhary LN, Johnson MK, Huang CC, Teshome M, Kong AL, Singh P, Cortina CS. National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial. Breast Cancer Res Treat. 2024 Jan;203(2):317-328. PMCID: PMC10872271
25. Gonzalez T, Nie Q, Chaudhary LN, Basel D, Reddi HV. Methylation signatures as biomarkers for non-invasive early detection of breast cancer: A systematic review of the literature. Cancer Genet. 2024 Apr;282-283:1-8.
26. Alaklabi S, Roy AM, Chaudhary LN, Gandhi S. Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline <i>BRCA</i> mutation? Explor Target Antitumor Ther. 2023;4(6):1301-1309. PMCID: PMC10776593
27. Kamaraju S., Jacquart A., Geurts J., Depas M., Stachowiak S., Olson J., Chaudhary LN., Chitambar CR., Cheng YC. “Disparities in genetic referrals among the Asian immigrant populations: How can we eliminate them?” Submitted for publication.
 
Abstracts
1. Hamadani M., Padmanabhan R., Chaudhary L., Tfayli A.: "Relative efficacy of various 5- hydroxytryptamine receptor antagonists in the prevention and control of acute nausea and vomiting associated with platinum-based chemotherapy." Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings. Vol 24, No. 18S (June 20 Supplement), 2006: 23.
2. Chaudhary L., Craig MD.: "Association of Primary Cutaneous γδ T-cell Lymphoma with Hemophagocytic Lymphohistiocytosis." Poster Presentation at ACP West Virginia Chapter Scientific Meeting, Roanoke, WV, October 2010.
3. Chaudhary L., Wilkinson R., Jordan C., Price A., Filburn S., Abraham J.: "Bevacizumab induced Nasal Septal Perforation. Management and Literature Review."Poster Presentation at ACP West Virginia Chapter Scientific Meeting, Roanoke, WV, October 2010.
4. Chaudhary L., Bailey NG., Vos JA., Stotler CJ.: "Unique association of myeloid neoplasm with eosinophilia and abnormalities of PDGFRA with TTP." Poster Presentation at ACP West Virginia Chapter Scientific Meeting, Roanoke, WV, October 2010.
5. Chaudhary L., Wilkinson R., Jordan C., Price A., Filburn S., Abraham J.: "Nasal Septal Perforation induced by Bevacizumab Therapy. Risk Factors & Management." Poster Presentation at GME Week, West Virginia University, 2010.
6. Kanate AS., Chaudhary L., Cumpston A., Leadmon S., Bunner P., Bulian D., Gibson L., Tse W., Abraham J., Remick S., Craig M., Hamadani M.: "High rates of non-relapse mortality and graft-versus-host disease in patient undergoing allogeneic stem cell transplantation following non-myeloablative conditioning with TLI/ATG." Biology of Blood and Marrow Transplantation. February 2011;17(2):S313. Poster Presentation.
7. Chaudhary L., Awan F., Cumpston C., Tse W., Craig M., Hamadani M.: "Efficacy and cost of peripheral blood stem cell (PBSC) mobilization with low-dose cyclophosphamide (LD-CY) compared with plerixafor (P) in multiple myeloma (MM) patients (pts) treated with novel induction therapies." Poster Presentation at ASCO Annual Meeting, Chicago, IL, June 2013.
8. Chaudhary L., Knapp S., Hester S., Wen S., Xiao J., Marano G., Kurian S., Hazard H., Layne G., Jacobson G., Abraham J.: "Radiation exposure in patients with newly diagnosed breast cancer within first year from diagnostic procedures." J Clin Oncol 31, 2013 (suppl 26; abstr 123). Poster Presentation at Breast Cancer Symposium, San Francisco, CA, Sept 2013.
9. Chaudhary L., Wen S., Xiao J., Swisher A., Kurian S., Abraham J.: "Weight change in patients with treatment of breast cancer." J Clin Oncol 31, 2013 (suppl 26; abstr 127). Poster Presentation at Breast Cancer Symposium, San Francisco, CA, Sept 2013.
10. Chaudhary L., Jawa Z., Szabo A., Visotcky A., Chitambar C.: "Inverse relationship between ER+/PR- breast cancer and OncotypeDx scores and Concordance between IHC and RT-PCR". Poster Presentation at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2014.
11. Chaudhary LN., Jawa Z., Hanif A., Szabo A., Chitambar CR.: “Ductal carcinoma in situ: patient outcomes and association with hormone receptors.” Poster Presentation at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2016.
12. Chaudhary LN., Peck AR., Sun Y., Hu H., Kovatich AJ., Hooke JA., Shriver CD., Mitchell EP., Chervoneva I., Rui H. “High Levels of Bruton’s Tyrosine Kinase (BTK) Protein is Associated with Favorable Outcome in Breast Cancer.” Poster Presentation at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2017.
13. Glisch C., Jawa ZA., Badar T., Visotcky A., Chaudhary LN., Kamaraju S., Burfeind JD., Charlson JA., Chitambar CR., Lagunova V., Aguilera-Barrantes I., Jorns J., Cheng YC. “Androgen receptor expression in patients with triple negative breast cancer treated with neoadjuvant chemotherapy: A single institution experience.” J Clin Oncol 36, 2018 (suppl; abstr e12662). Publication abstract at ASCO Annual Meeting, Chicago, IL, June 2018.
14. Jawa ZA., Glisch C., Badar T, Chaudhary LN., Kamaraju S., Burfeind JD., Charlson JA., Chitambar CR., Aguilera-Barrantes I., Jorns J., Lagunova V., Cheng YC. “Morbid obesity is related with adverse outcomes in triple negative breast cancer: A single institution experience.” J Clin Oncol 36, 2018 (suppl; abstr e12663). Publication abstract at ASCO Annual Meeting, Chicago, IL, June 2018
15. Chaudhary LN., Jorns JM., Gonyo MB., Kong A., Peck AR., Sun Y., Bergom C., Banarjee A., Chitambar CR., Rui H. “HER2 up-regulation with neoadjuvant endocrine therapy in patients with hormone receptor-positive, HER2-negative breast cancer.” Poster Presentation at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2019.
16. Cheng YC., O’Regan R., Chaudhary LN., Kamaraju S., Einhorn H., Sampene E., Pigsley M., Burkard ME., Chitambar CR, Wisinski KB. “A Phase II Study of Neoadjuvant Weekly Carboplatin/Paclitaxel followed by Dose-Dense Doxorubicin/Cyclophosphamide (DD AC) in Patients with Triple Negative Breast Cancer (TNBC): Wisconsin Oncology Network (WON) Study.” Poster Presentation at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2020.
17. Chaudhary LN., Jorns JM., Gonyo MB., Cheng YC., Kamaraju S., Kong A., Patten C., Yen T., Cortina C., Carson E., Bergom C., Banarjee A., Wang Y., Chitambar CR., Rui H. “Neoadjuvant Endocrine Therapy Helps Identify HER2 Up-regulation in Patients with Hormone Receptor-Positive HER2-Negative Breast Cancer.” ‘Spotlight’ Poster Discussion at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2020.
18. Zurko J., Szabo A., Cheng YC., Kamaraju S., Burfeind J., Retseck J., Chitambar CR., Chaudhary LN. “Matched Case Control Analysis of Breast Cancer Specific Factors Impacting Risk of Developing SARS-Cov-2 Infection.” Publication abstract at ASCO Annual Meeting, Chicago, IL, June 2021.
19. Kamaraju S., Wisinski K, Fowler A., Cheng YC., Chaudhary LN., Burfeind J., Retseck J., Tevaarwerk A., Paplomata E., Parkes A., Jorns JM., Rui H., Lange C. “The SMILE STUDY: A Phase II Trial of OnapriStone in CoMbInation with FuLvestrant for Patients with ER-positive and HER2-negative Metastatic Breast Cancer after Progression on Endocrine therapy and CDK 4/6 Inhibitors.” Poster Presentation at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2021
20. Chaudhary LN., Jorns JM., Cheng YC., Kamaraju S., Burfeind J., Gonyo MB., Kong A., Patten C., Yen T., Cortina C., Carson E., Johnson N., Bergom C., Banarjee A., Wang Y., Chervoneva I., Sun Y., Chitambar CR., Rui H. “HER1-4 Protein Up-Regulation Following Short-term Neoadjuvant Endocrine Therapy in Patients with Hormone Receptor-Positive HER2-Negative Breast Cancer.” Poster Presentation at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2021
21. Chaudhary LN., Chervoneva I., Peck AR., Sun Y., Yi M., Langenheim JF., Jorns JM., Kamaraju S., Cheng YC., Burfeind J., Chitambar CR., Hooke JA., Kovatich A., Shriver CR., Hu H., Palazzo JP., Bibbo M., Hyslop T., Pestell RG., Mitchell EP., Rui H. “High PD-L2 protein expression in cancer cells is an independent marker of unfavorable prognosis in luminal breast tumors.” Poster Presentation at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2022.
22. Monahan K., Kamaraju S., Cheng YC., Retseck J., Sriram D., Burfeind J., Chitambar CR., MD; Chaudhary LN. “Real World Statistics on CDK4/6 Inhibitor Use in Metastatic Hormone Receptor Positive and HER2-Negative Breast Cancer.” Poster Presentation at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2022.
23. Cotchett KR., Kelly AH., Szabo A., Cheng YC., Kamaraju S., Burfeind J., Chitamber CR., Wallace L., Chaudhary LN. “Depression and Psychological Distress in Breast Cancer Patients.” Poster Presentation at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2022.
24. Kamaraju S., Fowler A., Chaudhary L., Burkard M., Giever T., Cheng YC., Parkes A., Jorns JM., Retseck J., Sriram D., Tarima S., Rui H., Lange C, Wisinski K. “The SMILE Study: A phase II trial of onapristone in combination with fulvestrant for patients with ER-positive and HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK 4/6 inhibitors.” Poster Presentation at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2022.
25. Conroy M., Powell M., Nagavally S., Dawson AZ., Beckius A., Sweeney M., Min H., Weil E., Halbach A., Cheng YC., Chaudhary L., Wright T., Charlson J., Kamaraju S. “Addressing Healthcare Gaps and Disparities in Electronic Medical Record Messages: A Quality Improvement Project Among Breast Cancer Patients.” Poster Presentation at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2022.
26. Min H., Weil E., Nelson M., Charlson J., Conroy M., Powell M., Cheng YC., Chaudhary L., Burfeind J., Retseck J., Sriram D., Kamaraju S. “Improving Health-Related Quality of Life with Outpatient High-Dose Methotrexate Regimen Among Breast Cancer Oncology Patients with Intracranial Metastases: A Qualitative Study Submission.” Poster Presentation at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2022.
27. Chaudhary LN., Jorns JM., Sun Y., Kamaraju S., Cheng YC., Kong A., Yen T., Patten C., Cortina C, Chervoneva I., Chitambar CR., Hallgeir Rui. “Frequent Discordance in PD-L1 and PD-L2 Protein Expression in Breast Cancer.” Poster Presentation at ESMO Breast Cancer 2023. https://doi.org/10.1016/j.esmoop.2023.101296
28. Harris A., Szabo A., Kamaraju S., Cheng YC., Burfeind J., Chitambar CR., Chaudhary LN. “Impact of Neighborhood Disadvantage on Stage at Diagnosis and Outcomes in Women Diagnosed with Breast Cancer.” Publication abstract at ASCO Annual Meeting, Chicago, IL, June 2023.
29. Rogers C., Lloren JI., Johnson MK., Cobb A., Chaudhary LN., Huang C., Teshome M., Singh P., Kong AL., Cortina CS. “National trends in neoadjuvant chemotherapy utilization for cT1-2 N0 triple negative breast cancer: Did the CREATE-X trial impact treatment patterns?” Publication abstract at ASCO Annual Meeting, Chicago, IL, June 2023.
30. Kiran Manjee., Lubna N. Chaudhary., Nathan Kopp., Kathleen M. Bone., Hallgeir Rui, MD., Julie M. Jorns. “HER2 Upregulation following Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer.” Poster Presentation at CAP23 Pathology Meeting, Oct 2023.
31. David R. Spigel., Erika Hamilton., Babar Bashir., Usama Gergis., Hemant S. Murthy3., Saranya Chumsri., Yazan Migdady., Jennifer M. Specht., Lubna N. Chaudhary., Haven R. Garber., Chul Kim., Hirva Mamdani., Amer Beitinjaneh., Jonathan Goldman., Roberto A. Leon-Ferre., R. Alejandro Sica1., Brenda J. Ernst., Michael Hurwitz., Roisin E. O’Cearbhail., Sarah Fitzsimmons., Bishwa Ganguly., Hajime Hiraragi., Helle Jensen., Yeonhee Kim., Mary C. Lessig., and Heidi H. Gillenwater. “Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).” Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023.
32. Alaklabi S., Roy AM., Zagami P., Held N., Shaikh S., Chaudhary LN., Abdou Y., Shipra Gandhi S. “Real World Outcomes with Sacituzumab Govitecan in Metastatic Triple Negative Breast Cancer Patients: A Multi-Institution Study.” Poster Presentation at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2023.
33. Chaudhary LN., Jorns JM., Sun Y., Kamaraju S., Cheng YC., Kong A., Yen T., Patten C., Cortina C, Chervoneva I., Chitambar CR., Rui H. “PD-L1 and PD-L2 Protein Expression is Frequently Discordant in Breast Cancer.” Poster Presentation at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2023.